G>C SNP of thymidylate synthase with respect to colorectal cancer

Pharmacogenomics

Volumn 8, Issue 8, 2007, Pages 985-996

  Gusella, Milena ^a   Padrini, Roberto ^b  

^a ROVIGO GENERAL HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Colorectal cancer; Fluorouracil; G>C SNP; Genotyping; Objective response; Survival; Thymidylate synthase; Toxicity

Indexed keywords

CAPECITABINE; CARBOPLATIN; CARMOFUR; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; INTERFERON; IRINOTECAN; KRESTIN; LEVAMISOLE; OXALIPLATIN; RALTITREXED; TEGAFUR; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UFT; UPSTREAM STIMULATORY FACTOR 1;

5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; COMPUTER PROGRAM; DRUG RESPONSE; E BOX ELEMENT; ENZYME ANALYSIS; ENZYME REGULATION; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE LEVEL; TRANSLATION REGULATION; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; COLORECTAL NEOPLASMS; CYTOSINE; GUANINE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; THYMIDYLATE SYNTHASE;

EID: 34548706595     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.8.985     Document Type: Review

References (49)

1. Kaneda S, Nalbantoglu J, Takeishi K et al.: Structural and functional analysis of the human thymidylate synthase gene. J. Biol. Chem. 265. 20277-20284 (1990).
2. Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J. Clin. Oncol. 22, 529-536 (2004).
3. Edler D, Glimelius B, Hallström M et al.: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J. Clin. Oncol. 20. 1721-1728 (2002).
4. Takenoue T, Nagawa H, Matsuda K et al.: Relation between thymidylate expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann. Surg. Oncol. 7, 193-198 (2000).
5. Yamachika T, Nakanishi H. Inada, K et al.: A new prognostic factor for colorectal carcinoma, thymidylate synthase. and its therapeutic significance. Cancer 82, 70-77 (1998).
6. Santini D, Vincenzi B, Perrone G et al.: Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. Oncology 67, 135-142 (2004).
7. Carlini LE, Meropol NJ, Bever J et al.: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res. 11, 1226-36 (2005).
8. Marsh S, McLeod HL: Thymidylate synthase pharmacogenetics in colorectal cancer. Clin. Colorectal Cancer 1, 175-178 (2001).
9. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct, Funct. 20, 191-197 (1995).
10. Kawakami K, Omura K, Kanehira E, Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res, 19, 3249-3252 (1999).
11. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1. 65-70 (2001).
12. Kawakami K, Salonga D, Park JM et al.: Different length of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. 7, 4096-4101 (2001).
13. Takeishi K, Kaneda S, Ayusawa D, Shimizu K, Gotoh O, Seno T. Nucleotide sequence of a functional cDNA for human thymidylate synthase. Nucleic Acid Res. 13, 2035-2043 (1985).
14. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T, Altman S: Role in translation of a triple tandemly repeated sequence in the 5′-untransalted region of human thymidylate synthase mRNA. Nucleic Acids Res. 15, 1259-1270 (1987).
15. Chu E, Koeller DM, Casey JL et al.: Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc. Natl. Acad. Sci. USA 88, 8977-8981 (1991).
16. Chu E, Weller D. Koeller DM et al.: Identification of an RNA binding site for human thymidylate synthase. Proc. Natl Acad. Sci. USA 90, 517-521 (1993).
17. Lin X, Parsels LA, Voeller DM et al.: Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA. Nucleic Acids Res. 28, 1381-1389 (2000).
18. Mandola MV, Stoehlmacher J. Muller-Weeks S et al.: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63, 2898-2904 (2003).
19. Kawakami K, Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 63, 6004-6007 (2003).
20. Gusella M. Bolzonella C, Crepaldi G, Ferrazzi E, Padrini R: A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele. Pharmacogenomics J. 6: 421-424 (2006).
21. Lincz LF, Scorgie FE, Garg MB, Ackland SP: Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele. Int. J. Cancer 120, 1930-1934 (2007).
22. Mandola MV, Stoehlmacher J. Zhang W et al.: A 6bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumor TS mRNA levels. Pharmacogenetics 14, 319-327 (2004).
23. Nief N, LeMorvan V, Robert J: Involvement of gene polymorphism, of thymidylate synthase in gene expression. protein activity and anticancer drug citotoxicity using the NCI-60 panel. Eur. J Cancer 43, 955-962 (2007).
24. Kim SR, Ozawa S, Saito Y et al.: Fourteen novel genetic variations and haplotype structures of the TYMSgene encoding human thymidylate synthase (TS). Drug Metab. Pharmacokinet. 21, 509-516 (2006).
25. Fernandez-Contreras ME, Sanchez-Prudencio S, Sanchez-Hernandez JJ et al.: Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int. J. Oncol. 28. 1303-1310 (2006).
26. Marcuello E, Altes A. del Rio E, Cesar A, Menoyo A, Baiget M: Single nucleotide polymorphism In the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int. J. Cancer. 112, 733-737 (2004).
27. Morganti M, Ciantelli M, Giglioni B et al.: Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur. J. Cancer. 41, 2176-2183 (2005).
28. Stoehlmacher J, Park DJ, Zhang W et al.: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91. 344-354 (2004).
29. Terrazzino S. Agostini M. Pucciarelli S et al.: A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative cbemoradiation. Pharmacogenet. Genomics 16, 817-824 (2006).
30. Tsuji T, Hidaka S, Sawai T et al.: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin. Cancer Res. 9. 3700-3704 (2003).
31. Zhu AX, Puchalski TA, Stanton VP Jr et al.: Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Clin. Colorectal Cancer 3. 225-234 (2004).
32. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism In the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer. 85, 827-830 (2001).
33. Marsh S, McKay JA, Cassidy J, McLeod HL: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 19, 383-386 (2001).
34. Matsui T, Omura K, Kawakami K, Morita S, Sakamoto J: Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer. Oncol. Rep. 16, 1111-1115 (2006)
35. Park DJ. Stoehlmacher J. Zhang W, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int. J. Colorectal Dis. 17, 46-49 (2002).
36. Villafranca E, Okruzhnov Y, Dominguez MA et al.: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19, 1779-1786 (2001).
37. Massacesi C, Terrazzino, S, Marcucci F et al.: Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism. predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106, 1007-1016 (2006).
38. Lecomte T, Ferraz JM, Zinzindohoue F et al.: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 10, 5880-5888 (2004).
39. Ichikawa W. Takahashi T, Suto K, Sasaki Y, Hirayama R: Orotate phosphoribosyltransferase gene polymorphism predicts toxicity inpatients treated with bolus 5-fluorouracil regimen. Clin. Cancer Res. 12. 3928-3934 (2006).
40. Dotor E, Cuatrecases M, Martinez-Iniesta M et al.: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J. Clin. Oncol. 24, 1603-1611 (2006).
41. Hitre E, Budai B, Adleff V et al.: Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet. Genomics 15, 723-730 (2005).
42. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J: Thymidylate synthase and methylenetetrahydrofolate reductase gene pplymorphism in normal tissue as predictors of fluorouracil sensitivity. J. Clin. Oncol 23, 1365-1369 (2005).
43. Etienne MC, Chazal M, Laurent-Puig P et al.: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J. Clin. Oncol. 20, 2832-2843 (2002).
44. Uchida K, Hayashi K, Kawakami K et al.: Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin. Cancer Res. 10. 433-439 (2004).
45. Yawata A, Kim SR, Myajima A et al.: Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents. Cancer Chemother. Pharmacol. 56. 465-472 (2005).
46. Amatori F, di Paolo A, del Tacca M et al.: Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenet. Genomics 16, 809-816 (2006).
47. Etienne MC, Formento JL, Laurent-Puig P et al.: Thymidylate synthase and methylenetetrahydrofolate reductase-gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br. J. Cancer. 90, 526-534 (2004).
48. Gusella M, Crepaldi G, Barile C et al.: Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal patients. Ann. Oncol. 17, 1656-1660 (2006).
49. Bocci G, Barbara C, Vannozzi F et al.: A phamacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin. Pharmacol. Ther. 80, 384-395 (2006).